Powell says Fed doesn’t need to hurry to cut interest rates
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Republicans clinch control of House, setting stage for quicker action on extending tax cuts
This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho
Cava is riding a strong wave, but the stock’s quadrupling in 2024 has analysts wary
Wells Fargo touches all-time high as analyst hikes price target to new level
Tesla is likely to thrive in a Trump administration. These are the ways these analysts see it happening.
Dogecoin soars as altcoins look to benefit from Trump presidency
